Company intelligence / Profile preview

Keythera Pharmaceuticals

Ownership: Private
Employees: ~30
Development stage: Phase 2

Overview

Lead product KF-0210 (EP4 receptor antagonist) is in Phase 2 clinical trials for osteoarthritis and Phase 1b for solid tumors. Another product, KBP-2205, has completed preclinical candidate validation studies and entered pre-clinical study stage.

Therapeutic areas: OncologyImmunologyRheumatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

KF-0210

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Keythera Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keythera Pharmaceuticals.